Anti-Emetics Would Be Paid Separately Under Medicare Outpatient Rule
Executive Summary
The chemotherapy-induced nausea treatments Anzemet, Kytril and Zofran would be reimbursed separately rather than bundled with a package of therapeutic services under the 2005 Medicare outpatient prospective payment system proposed rule
You may also be interested in...
Medicare Payments For Unbundled Drugs Needs Revision, MedPAC Says
The Centers for Medicare & Medicaid Services should change how it sets payments for unbundled hospital outpatient drugs once a provision in the 2003 Medicare law expires, the Medicare Payment Advisory Commission said
Medicare Payments For Unbundled Drugs Needs Revision, MedPAC Says
The Centers for Medicare & Medicaid Services should change how it sets payments for unbundled hospital outpatient drugs once a provision in the 2003 Medicare law expires, the Medicare Payment Advisory Commission said
Faslodex, Aranesp Have Special Status Under Hospital Payment Rule
CMS is proposing to allow separate Medicare payments for Faslodex, Trelstar and argatroban use in the hospital outpatient setting when the products become ineligible for "pass-through" payments in 2005